Lilly trades at a premium to Ozempic-maker Novo as obesity d

Deutsche Bank analyst James Shin says there are several reasons why Lilly should trade at a premium to Novo Nordisk.

Related Keywords

United States , American , Chris Schott , Novo Nordisk Ozempic , David Ricks , James Shin , Karsten Munk Knudsen , Lilly Mounjaro , Eli Lilly , Novo Nordisk , American Heart Association , Deutsche Bank , Centers For Disease , Astrazeneca , Does Eli Lilly , For Deutsche Bank , Wall Street , Inflation Reduction Act , Disease Control , Munk Knudsen , Biotech And Pharmaceuticals , Health Care Industry , Breaking News Investing , Eli Lilly And Co , Investment Strategy , Novo Nordiska S , Astrazeneca Plc , Business News ,